Kisters K, Gremmler B, Schmidt J, Gröber U and Tokmak F
According to the results of the MACH study additional magnesium orotate therapy has shown a positive effect on life expectancy and quality of life in patients with severe forms of heart insufficiency. Both magnesium and orotate can be cardio protective. In the presented data here additional magnesium orotate therapy was tested in 11 patients with hypertensive heart disease NYHA III-IV as compared to 10 patients with hypertensive heart disease NYHA II-IV as controls. Additional magnesium orotate therapy was 4500 mg magnesium orotate daily for 1 week. NTproBNP levels decreased significantly in the magnesium orotate group versus controls (p<0.01). Under therapy quality of life improved significantly as well. Kidney function remained stable in the normal range.
In conclusion an additional therapy with magnesium orotate is safe and can be of additional benefit in hypertensive heart disease with insufficiency.
There is an improvement in quality of life and life expectancy in heart insufficiency under an additional magnesium orotate therapy.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 